February 28, 2023 10:38 AM ESTUpdated March 1, 07:18 AM

Chinook delays topline kidney condition data; Eluminex ropes in $40M+ in a Series B

Katherine Lewin

News Reporter

Tyler Patchen

News Reporter

Chinook’s readout of its Phase III ALIGN trial of atrasentan, a potential treatment for chronic kidney diseases, could be delayed by about three months, …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chinook delays topline kidney condition data; Eluminex ropes in $40M+ in a Series B

Katherine Lewin

News Reporter

Tyler Patchen

News Reporter

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?

Chi­nook de­lays topline kid­ney con­di­tion da­ta; Elu­minex ropes in $40M+ in a Se­ries B

News Reporter

News Reporter

Sign up to read this article for free.

Chinook delays topline kidney condition data; Eluminex ropes in $40M+ in a Series B